timothy sykes logo
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial Thumbnail
ADD US ONG Google News

AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial

JACK KELLOGG•UPDATED MAR. 18, 2026, 9:19 AM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

AIM ImmunoTech Inc.’s stocks have been trading up by 118.31 percent after FDA designations and promising results boosted investor confidence.

Candlestick Chart

Live Update At 09:18:57 EDT: On Wednesday, March 18, 2026 AIM ImmunoTech Inc. stock [NYSE American: AIM] is trending up by 118.31%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick financial overview

The stock prices for AIM have recently shown movement, a dance of figures responding to the buzzing noise of innovation. Across the days, there’s been a bit of a rollercoaster: from 0.7314 down to 0.71 by the latest close. A tale of numbers that reflect decisions, trials, and potential life-changing solutions. AIM’s stock opened at 0.7314 on Mar 17, 2026, and dipped slightly by day’s end—an everyday story for penny stocks caught in the waves of new, hopeful ventures.

What’s more captivating is the share of movement seen on a minute-to-minute basis—a tale of quick moments as traders react with anticipation at the news. Peaks at 1.72 tell us one thing: Buzz is high. Low points dive to 0.69, perhaps a breath held before more revelations unfold.

Let’s talk about AIM’s past, their financial canvas showing hues of posh potential—and risks. Revenue sits at $170,000, a whisper compared to giants, yet enough to fuel ambition. Losses have been in tails, with ebit margins peeking into the negatives, but that’s a familiar playground in biotech circles where hopes anchor innovation.

The recent financial whistleblow relayed a tale of restructuring. Cash holdings, $2,347,000 strong, hint at a business natural in perpetuating its quest despite evident challenges. AIM has orchestrated liquidity prospects worth noting—operating cash flow reads a decent negative cadence, yet investments sing a chorus of hefty inflows.

Now accompanying these figures is the fresh pep from Ampligen’s clinical prowess. As stakeholder eyes dart to late 2026 for data validation, AIM’s stock trajectory might sway to bullish or cautious according to clinical thrill—that’s AIM’s storyline.

Market Reactions

A palpable stir seizes the market, setting AIM’s stock tremoring. Thermo Fisher joining the Phase 3 endeavors affixes a badge of credibility. Here, partnerships considerably color corporate tales, and in biotech land, they resonate with investors who cherish the alliance’s gleam. Ampligen, a name alchemizing through trials, possesses the cogs to redefine AIM’s landscape if late-stage triumphs beckon it onward.

The rekindling segue for the ongoing Phase 2 DURIPANC has to whet both traders’ and analysts’ palate. Announced milestones and not so distant readouts offer a narrative brimming with cautious optimism. Success isn’t just a word; it’s a sequence of coordinated steps, and the very DNA of these trials threads AIM’s tomorrow. Aspirants eye 2026 closely, but it’s today’s whispers on collaborations that keep AIM relevant.

Narratives of biotech evolution float sentiments steadfastly, reflecting potential in pharmaceutical advances, alongside moral gratifications—wiping the abstract notion of pancreatic cancer survival nearer toward tangible outcomes.

More Breaking News

Conclusion

Talents joined in great design often accentuate triumphs similar to a play’s crescendo. Partners like Thermo Fisher sharpen AIM’s trials, illuminating pathways for future achievements. With foundations built on scientific rigor and ambitious timelines, the possibility to make strides in pancreatic cancer treatment is tangible.

AIM, through Ampligen’s remit, seems set on sculpting a horizon where the firm is not just an observer but a catalyst. The stage? A complex biotech canvas, but one with ground fertile for those who dare to seize it. Stock price movements flitting agilely embrace anticipation or pause, as traders weigh risks against grand opportunities.

While AIM’s story unfolds in trial timeliness and innovative adventures, tales entwined with strategy will be the compass guiding informed traders as they measure their next steps over AIM’s financial terrain. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This wisdom complements AIM’s approach, reminding traders that consistent progress in biotech can mirror effective trading—focusing on sustainable growth rather than fleeting highs.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading [TICKER]

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”